Native T1 Mapping by Cardiovascular Magnetic Resonance Imaging in Rare Diseases

Fabry Disease Clinical Trial

— FABRY400  

Official title:

Native T1 Mapping by Cardiovascular Magnetic Resonance Imaging in Rare Diseases- A New Method to Improve Patient Care

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03199001
• Other study ID #: 14/0354
• Status: Recruiting
• Phase: N/A
• First received: June 19, 2017
• Last updated: June 23, 2017
• Start date: February 19, 2015
• Est. completion date: February 19, 2019

Study information

• Verified date: June 2017
• Source: University College, London
• Contact: James Moon, MD
• Email: j.moon[@]ucl.ac.uk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Fabry Disease (FD) is a rare, X-linked lysosomal storage disorder leading to left ventricular hypertrophy, myocardial fibrosis, arrhythmia and heart failure. Cardiac involvement is the leading cause of death in FD. Treatment with enzyme replacement therapy is expensive, may be poorly targeted and there are difficulties in early detection and disease monitoring. T1 mapping signal change is a potential remarkable biomarker for FD.

Fabry400 is a multicentre study aiming to understand the biology of Fabry Disease and its relationship to non-invasive multi parametric mapping by CMR.

Description:

Our understanding of cardiac involvement in FD is limited because the myocyte storage cannot be assessed non-invasively. However with the development of CMR T1 mapping this maybe possible. T1 mapping demonstrated excellent discrimination between FD and other causes of LVH, and this property is highly suggestive of a direct but intricate relationship between T1 signals and abnormal fat storage. Specifically, 50% of patients without LVH have low T1 values, suggesting that T1 is an early disease marker in FD. This property may prove particularly useful for assessing disease progression and treatment response in early disease.

In CMR, LGE in FD characteristically occurs in the basal inferolateral wall. LGE is associated with a poor response to therapy and adverse outcomes. Hybrid imaging with PET/MR has shown that some FD LGE may be inflammation. T2 mapping may be useful as it is a sensitive detector of inflammation and oedema, for example discriminating acute from chronic myocardial infarction, and diagnosing myocarditis, particularly in the setting of chronic myocarditis or heart failure.

The aims of this study are:

1. Improve the diagnosis of cardiac involvement by recognition of early disease

2. Detect early changes and responses to therapy

3. Improve the understanding of the pathophysiology of cardiac involvement using multiparametric mapping by CMR

Study Method:

This is a cohort observational study of FD patients including children, patients starting ERT, ERT naïve patients and LVH positive patients. Follow up scans at 6 months and 12 months will be done on patients starting ERT. CMR Scanning will use T1 and T2 mapping techniques against established gold-standard sequences. The patients will also have ECHO and ECG. Blood biomarkers will be collected (serum, plasma and urine).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 400
• Est. completion date: February 19, 2019
• Est. primary completion date: August 19, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 9 Years and older

Eligibility

Inclusion Criteria:

• Gene-positive Fabry Disease

• Male or female

• Age at least 9 years

Exclusion Criteria:

• Any absolute contraindication to CMR

• Pregnancy

Related Conditions & MeSH terms

• Fabry Disease
• Rare Diseases

Locations

Country	Name	City	State
Australia	University of Sydney	Sydney
United Kingdom	University Hospital Birmingham	Birmingham
United Kingdom	Royal Free Hospital	London
United Kingdom	The Heart Hospital, University College London Hospital	London

Sponsors (3)

Lead Sponsor	Collaborator
University College, London	University Hospital Birmingham, University of Sydney

Countries where clinical trial is conducted

Australia,  United Kingdom, 

References & Publications (3)

Nappi C, Altiero M, Imbriaco M, Nicolai E, Giudice CA, Aiello M, Diomiaiuti CT, Pisani A, Spinelli L, Cuocolo A. First experience of simultaneous PET/MRI for the early detection of cardiac involvement in patients with Anderson-Fabry disease. Eur J Nucl Med Mol Imaging. 2015 Jun;42(7):1025-31. doi: 10.1007/s00259-015-3036-3. Epub 2015 Mar 26. — View Citation

Pica S, Sado DM, Maestrini V, Fontana M, White SK, Treibel T, Captur G, Anderson S, Piechnik SK, Robson MD, Lachmann RH, Murphy E, Mehta A, Hughes D, Kellman P, Elliott PM, Herrey AS, Moon JC. Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2014 Dec 5;16:99. doi: 10.1186/s12968-014-0099-4. — View Citation

Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, Fontana M, Maestrini V, Flett AS, Robson MD, Lachmann RH, Murphy E, Mehta A, Hughes D, Neubauer S, Elliott PM, Moon JC. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013 May 1;6(3):392-8. doi: 10.1161/CIRCIMAGING.112.000070. Epub 2013 Apr 5. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Presence of storage in Fabry cardiomyopathy	Presence or absence of storage (measured in milliseconds) by T1 mapping by CMR	1 hour
Secondary	Presence of inflammation in Fabry cardiomyopathy	Presence or absence of inflammation (measured in milliseconds) by T2 mapping by CMR	1 hour
Secondary	Change in storage measure	Change in storage measure (measured in milliseconds) by T1 mapping by CMR	12 months